By Chris Wack

Sientra Inc. said the U.S. Food and Drug Administration approved the Low Plus Profile Projection Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction.

The company said the product will be commercially available for board-certified and board-eligible plastic surgeons in the U.S. in late July.

Sientra shares were up 13% to 99 cents in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 06, 2022 09:29 ET (13:29 GMT)

Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Jul 2022 to Aug 2022

Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Aug 2021 to Aug 2022